Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Achieves Janssen Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Genmab Achieves Janssen Milestone

Advances Phase II trial in follicular lymphoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has reached a $5 million milestone in its daratumumab collaboration with Janssen Biotech triggered by progress in the ongoing Phase II study (“Carina” LYM2001) in NHL.
 
The study evaluates daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). This milestone is related to progress in the arm of the study treating patients with FL.
 
“The daratumumab study in NHL is now underway, and we are very pleased to have achieved milestones for progress in two of the disease areas included in the study, FL and DLBCL,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab. “We remain optimistic about the therapeutic potential of daratumumab in indications outside of multiple myeloma.”
 
Daratumumab has received Orphan Drug designation from the FDA for DLBCL, MCL and FL.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics